Tirzepatide activates two receptors — GLP-1 and GIP — while semaglutide only hits GLP-1. That dual mechanism gives tirzepatide a stronger impact on appetite, insulin sensitivity, and fat metabolism. In the SURMOUNT-1 clinical trial of brand-name tirzepatide, patients lost an average of up to 22.5% of their body weight over 72 weeks — the strongest weight loss ever measured for an approved weight-management medication.

Same active ingredient — tirzepatide — but not the same product. Mounjaro® (approved for type 2 diabetes) and Zepbound® (approved for chronic weight management) are FDA-approved brand-name medications made by Eli Lilly. Our compounded tirzepatide is prepared by U.S. state-licensed compounding pharmacies and is not individually FDA-approved. Compounded versions are typically more affordable and help patients access the medication during brand-name shortages.

Because the dual mechanism is more powerful, the GI side effects during dose titration — nausea, diarrhea, constipation, abdominal pain — can also be more pronounced than semaglutide. The good news: these are managed by titrating the dose up slowly over weeks, eating smaller meals, staying hydrated, and messaging your provider when you need dose adjustments. Most women find side effects fade after the first 4–6 weeks.

Tirzepatide is a once-weekly subcutaneous injection you give yourself at home. The injection takes under 30 seconds with a tiny needle. Your first shipment includes everything you need — medication, syringes, alcohol swabs, and a step-by-step guide. Your care team is available 7 days a week if you need help.

Yes — this is important. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives, especially during the first 4 weeks of treatment and after each dose increase. Women of reproductive age should consider a non-oral method (IUD, implant, ring, patch) or add a barrier method (condoms) during those windows. Discuss contraception with your provider during intake.

Do not use tirzepatide if you or a family member has medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), if you’re pregnant or breastfeeding, or if you’ve had a serious allergic reaction to tirzepatide. Read our Important Safety Information page for all contraindications, boxed warnings, and side effects.